LeMaitre Vascular Files 8-K on Financials
Ticker: LMAT · Form: 8-K · Filed: Oct 31, 2024 · CIK: 1158895
| Field | Detail |
|---|---|
| Company | Lemaitre Vascular Inc (LMAT) |
| Form Type | 8-K |
| Filed Date | Oct 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, results-of-operations
TL;DR
LeMaitre Vascular dropped an 8-K on Oct 31st with financial updates. Check it out.
AI Summary
LeMaitre Vascular, Inc. filed an 8-K on October 31, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the report date and date of change both being October 31, 2024. The company is based in Burlington, MA.
Why It Matters
This 8-K filing provides investors with updated financial information and operational results for LeMaitre Vascular, Inc., crucial for assessing the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any unusual risks or events.
Key Players & Entities
- LeMaitre Vascular, Inc. (company) — Registrant
- October 31, 2024 (date) — Report Date
- Burlington, MA (location) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
This 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details of the financial results are not provided in the text excerpt.
When was this report filed and what is the period it covers?
The report was filed on October 31, 2024, and the 'Conformed Period of Report' and 'Date As Of Change' are also listed as October 31, 2024.
What is LeMaitre Vascular, Inc.'s principal executive office address?
The principal executive offices are located at 63 Second Avenue, Burlington, MA 01803.
What is the Commission File Number for LeMaitre Vascular, Inc.?
The Commission File Number for LeMaitre Vascular, Inc. is 001-33092.
What is the SIC code for LeMaitre Vascular, Inc.?
The Standard Industrial Classification (SIC) code for LeMaitre Vascular, Inc. is 3841, which corresponds to 'Surgical & Medical Instruments & Apparatus'.
Filing Stats: 735 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2024-10-31 16:02:53
Key Financial Figures
- $0.01 — nge on which registered Common stock , $0.01 par value per share LMAT The Nasdaq
Filing Documents
- lmat20241031_8k.htm (8-K) — 34KB
- ex_740933.htm (EX-99.1) — 365KB
- 0001437749-24-032784.txt ( ) — 548KB
- lmat-20241031.xsd (EX-101.SCH) — 3KB
- lmat-20241031_def.xml (EX-101.DEF) — 11KB
- lmat-20241031_lab.xml (EX-101.LAB) — 15KB
- lmat-20241031_pre.xml (EX-101.PRE) — 11KB
- lmat20241031_8k_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On October 31, 2024, LeMaitre Vascular, Inc. (the "Company") issued a press release regarding its preliminary financial and operational results for the quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Report. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. Disclaimer on Forward-Looking Statements This current report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include risks and uncertainties included under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. The following exhibits are furnished or filed as part of this Report, as applicable: (d) Exhibits. Exhibit No. Description 99.1 Press release issued by LeMaitre Vascular, Inc. on October 31, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Signature(s) Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LeMaitre Vascular, Inc. Date: October 31, 2024 By: Joseph P. Pellegrino, Jr. /s/ JOSEPH P. PELLEGRINO, JR. Joseph P. Pellegrino, Jr. Chief Financial Officer Exhibit Index Exhibit No. Description 99.1 Press release issued by LeMaitre Vascular, Inc. on October 31, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)